| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print October 10, 2003
Dermatology, Oregon Health & Science University, Portland, OR 97201
Corresponding Author: kuleszma{at}ohsu.edu
Mdm2 gene amplification occurs in benign and chemotherapy-responsive malignant tumors with wtp53 genes as well as in breast and epithelial cancers. Mdm2 amplification in benign tumors suggests that it is not sufficient for p53 inactivation in cancer, implying that other defects in the p53 pathway are required for malignancy. We investigated mechanisms of wtp53 protein inactivation in malignant conversion of epithelial cells by comparing clonally related initiated cells with their derivative cancerous cells that have mdm2 amplification. Deficiencies in p53 accumulation and activities in response to DNA damage were not due simply to Mdm2 destabilization of p53 protein, but to continued association of DNA-bound p53 with Mdm2 protein and lack of binding and acetylation by p300 protein. The aberrant interactions were not due to mdm2 amplification alone, since DNA-bound p53 protein from initiated cells failed to bind ectopically-expressed Mdm2 or endogenous overexpressed Mdm2 from cancerous cells. Phosphorylations of endogenous p53 at Ser18, 23, or 37 were insufficient to dissociate Mdm2, since each was induced by UV in cancerous cells. Interestingly, phospho-mimic p53-T21E did dissociate Mdm2 protein from DNA-bound p53 and recovered p300 binding and p21 induction in the cancerous cells. Thus wtp53 in malignant cells with mdm2 amplification can be inactivated by continued association of DNA-bound p53 protein with Mdm2 and failure of p300 binding and acetylation, coupled with a defect in p53 phosphorylation at Thr21. These findings suggest therapeutic strategies that address both p53:Mdm2 interaction and associated p53 protein defects in human tumors that have amplified mdm2 genes.
J. Biol. Chem, 10.1074/jbc.M300279200
Submitted on January 10, 2003
Revised on October 10, 2003
Accepted on October 10, 2003
Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Li, Y. Zheng, W. Chen, C. Wang, X. Liu, W. He, H. Xu, and X. Cao Adaptor Protein LAPF Recruits Phosphorylated p53 to Lysosomes and Triggers Lysosomal Destabilization in Apoptosis Cancer Res., December 1, 2007; 67(23): 11176 - 11185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Johnson, J. Lagowski, A. Sundberg, S. Lawson, Y. Liu, and M. Kulesz-Martin p73 Loss Triggers Conversion to Squamous Cell Carcinoma Reversible upon Reconstitution with TAp73{alpha} Cancer Res., August 15, 2007; 67(16): 7723 - 7730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ohkubo, T. Tanaka, Y. Taya, K. Kitazato, and C. Prives Excess HDM2 Impacts Cell Cycle and Apoptosis and Has a Selective Effect on p53-dependent Transcription J. Biol. Chem., June 23, 2006; 281(25): 16943 - 16950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Knights, J. Catania, S. D. Giovanni, S. Muratoglu, R. Perez, A. Swartzbeck, A. A. Quong, X. Zhang, T. Beerman, R. G. Pestell, et al. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate J. Cell Biol., May 22, 2006; 173(4): 533 - 544. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
